DOI 10.1007/s11011-026-01793-0
From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials.
Аннотация
Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive declination, neuronal loss, & multifaceted pathological mechanisms. Despite extensive scientific research, no definitive cure exists, but recent advancements in clinical trials highlight promising therapeutic strategies targeting multiple pathways involved in AD progression. Early-phase trials (Phases I and II) focus primarily on amyloid-beta (Aβ) and tau pathologies, with monoclonal antibodies like Aducanumab, Lacanemab, and Remternetug targeting Aβ clearance, while tau-directed agents such as E2814 and Bepranemab aim to reduce neurofibrillary tangle formation. Additionally, some novel approaches addressing neuroinflammation, bioenergetic disturbances, neurotransmitter modulation, and synaptic plasticity are emerging. In Phase III, late-stage candidates like Aducanumab, Donanemab, and Lecanemab have advanced, with some receiving regulatory approval, though their long-term clinical efficacy remains under evaluation. Phase IV studies further assess the long-term safety & effectiveness of approved treatments in real world populations. The evolving landscape of AD therapeutics underscores a paradigm shift towards combination therapies and personalized medicine, recognizing AD as a multifactorial disorder.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.